LABELS · bf994196-5149-4089-b1fc-c4f0cb8744b3

EPOGEN

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-23
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, E SA dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] . Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions ( 5.1 )] . Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Warnings and Precautions ( 5.2 )] . To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration ( 2.4 )] . Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage ( 1.3 )] . ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage ( 1.5 )] . Discontinue following the completion of a chemotherapy course [see Dosage and Administration ( 2.4 )] . Perisurgery: Due to increased risk of Deep Venous Thrombosis (DVT), DVT prophylaxis is recommended [see Dosage and Administration ( 2.5 ), Warnings and Precautions ( 5.1 )] . WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL ( 5.1 ). No trial has identified a hemoglobin target level, E SA dose, or dosing strategy that does not increase these risks ( 2.2 ) . Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions ( 5.1 ). Cancer : ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers ( 5.2 ). Use the lowest dose to avoid RBC transfusions ( 2.4 ). Use ESAs only for anemia from myelosuppressive chemotherapy ( 1.3 ) . ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). Discontinue following the completion of a chemotherapy course ( 2.4 ). Perisurgery : Due to increased risk of deep venous thrombosis ( DVT ) , DVT prophylaxis is recommended ( 5.1 ).

Indications and usage: exact source text

1 INDICATIONS AND USAGE Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disease Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV Infection Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL. 1.3 Anemia Due to Chemotherapy in Patients with Cancer Epogen is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.4 Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery Epogen is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. Epogen is not indicated for patients who are willing to donate autologous blood pre-operatively. 1.5 Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being. Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediate correction of anemia.

Full extracted label fields

application numbers

BLA103234

boxed warning exact

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, E SA dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] . Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions ( 5.1 )] . Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Warnings and Precautions ( 5.2 )] . To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration ( 2.4 )] . Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage ( 1.3 )] . ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage ( 1.5 )] . Discontinue following the completion of a chemotherapy course [see Dosage and Administration ( 2.4 )] . Perisurgery: Due to increased risk of Deep Venous Thrombosis (DVT), DVT prophylaxis is recommended [see Dosage and Administration ( 2.5 ), Warnings and Precautions ( 5.1 )] . WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL ( 5.1 ). No trial has identified a hemoglobin target level, E SA dose, or dosing strategy that does not increase these risks ( 2.2 ) . Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions ( 5.1 ). Cancer : ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers ( 5.2 ). Use the lowest dose to avoid RBC transfusions ( 2.4 ). Use ESAs only for anemia from myelosuppressive chemotherapy ( 1.3 ) . ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). Discontinue following the completion of a chemotherapy course ( 2.4 ). Perisurgery : Due to increased risk of deep venous thrombosis ( DVT ) , DVT prophylaxis is recommended ( 5.1 ).

brand names

EPOGEN

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

generic names

EPOETIN ALFA

bf994196-5149-4089-b1fc-c4f0cb8744b3

indications and usage exact

1 INDICATIONS AND USAGE Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disease Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV Infection Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL. 1.3 Anemia Due to Chemotherapy in Patients with Cancer Epogen is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.4 Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery Epogen is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. Epogen is not indicated for patients who are willing to donate autologous blood pre-operatively. 1.5 Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being. Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediate correction of anemia.

indications and usage tables exact

is original packager

true

manufacturer names

Amgen, Inc

matched search terms

cancer

package ndcs

55513-126-01
55513-126-10
55513-126-20
55513-267-01
55513-267-10
55513-267-20
55513-148-01
55513-148-10
55513-148-20
55513-144-01
55513-144-10
55513-144-20

product ndcs

55513-126
55513-267
55513-148
55513-144
55513-283
55513-478

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS
SUBCUTANEOUS

rxcuis

205912
205917
205921
205923
212218
239998
239999
240000
240377
241999
1721684
1721685

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA103234

brand names

EPOGEN

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 644
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 0

current approval status

not_reconciled

duplicate text group

dup-825308b12528432b11dd

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-d298c9d4838c7159b579

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

end: 85
end exclusive: true
exact text: is an erythropoiesis-stimulating agent (ESA) indicated
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 31

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 444
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 2 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 776
end exclusive: true
exact text: deficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, bi
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 245

current approval status

not_reconciled

duplicate text group

dup-fe475e97aaa9fa230c69

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-c60e5af3ebb99855ae08

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 576
end exclusive: true
exact text: Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 445

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · limitation of use

application numbers

BLA103234

brand names

EPOGEN

classification reasons

limitation_heading

clinical review status

pending

content role

limitation_of_use

context span

end: 889
end exclusive: true
exact text: a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In pat
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 377

current approval status

not_reconciled

duplicate text group

dup-b2239326bdafbb91bffc

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-7c90326358b6b5d1731a

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 689
end exclusive: true
exact text: Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 577

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · limitation of use

application numbers

BLA103234

brand names

EPOGEN

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1082
end exclusive: true
exact text: transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 490

current approval status

not_reconciled

duplicate text group

dup-982c8d5720422ba815b0

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-2d52447d8deb8210f0e6

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 882
end exclusive: true
exact text: Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 690

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 5 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1192
end exclusive: true
exact text: 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 683

current approval status

not_reconciled

duplicate text group

dup-a1929451ea15ac58d1ca

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-7692f38d78a3ff903c5d

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 992
end exclusive: true
exact text: In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 883

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1314
end exclusive: true
exact text: or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 793

current approval status

not_reconciled

duplicate text group

dup-b1fb20ba092eea9fbf77

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-09081baa05d7e4abfa62

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1114
end exclusive: true
exact text: In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 993

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1400
end exclusive: true
exact text: g myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disea
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 915

current approval status

not_reconciled

duplicate text group

dup-ab8af0f68865c5f29c01

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-da69f4a2da674f87bcdb

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1200
end exclusive: true
exact text: In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1115

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1460
end exclusive: true
exact text: nts with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disease Epogen is indicated for the treatment of anemia due to ch
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1001

current approval status

not_reconciled

duplicate text group

dup-ddec06ddc090ab21b919

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-a3ddc0203c38d7a13916

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1260
end exclusive: true
exact text: In patients undergoing cardiac or vascular surgery ( 1.5 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1201

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1561
end exclusive: true
exact text: hom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disease Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need f
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1061

current approval status

not_reconciled

duplicate text group

dup-d71d298f2b9e7515a173

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-05c621daec080067a16d

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1361
end exclusive: true
exact text: As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ).
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1261

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · positive indication candidate

application numbers

BLA103234

brand names

EPOGEN

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1797
end exclusive: true
exact text: ng to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disease Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV Infection Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endoge
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1162

current approval status

not_reconciled

duplicate text group

dup-2da1544feb838b31a379

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-47fc454aaeef2159d0c8

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

end: 1422
end exclusive: true
exact text: is indicated
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1410

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1597
end exclusive: true
exact text: 1.1 Anemia Due to Chronic Kidney Disease Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1362

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 11 · positive indication candidate

application numbers

BLA103234

brand names

EPOGEN

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2049
end exclusive: true
exact text: ease Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV Infection Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL. 1.3 Anemia Due to Chemotherapy in Patients with Cancer Epogen is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelo
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1398

current approval status

not_reconciled

duplicate text group

dup-0929d43c85687622ac51

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-fc63bab34042fb8933cf

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

end: 1677
end exclusive: true
exact text: is indicated
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1665

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1849
end exclusive: true
exact text: 1.2 Anemia Due to Zidovudine in Patients with HIV Infection Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1598

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · positive indication candidate

application numbers

BLA103234

brand names

EPOGEN

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2364
end exclusive: true
exact text: fection Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL. 1.3 Anemia Due to Chemotherapy in Patients with Cancer Epogen is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.4 Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery Epogen is indicated to reduce the need for allogeneic RBC transfusions among p
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1650

current approval status

not_reconciled

duplicate text group

dup-a0f0a8674d7efbcd0f65

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-7a8ea7f60eeeb1aa4c20

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

end: 1924
end exclusive: true
exact text: is indicated
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1912

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2164
end exclusive: true
exact text: 1.3 Anemia Due to Chemotherapy in Patients with Cancer Epogen is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1850

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 13 · positive indication candidate

application numbers

BLA103234

brand names

EPOGEN

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2717
end exclusive: true
exact text: with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.4 Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery Epogen is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. Epogen is not indicated for patients who are willing to donate autologous blood pre-operatively. 1.5 Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 1965

current approval status

not_reconciled

duplicate text group

dup-bbe1ed7a97bd25876b39

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-8736febc8060d62e0936

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

end: 2305
end exclusive: true
exact text: is indicated
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2293

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2517
end exclusive: true
exact text: 1.4 Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery Epogen is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2165

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 14 · limitation of use

application numbers

BLA103234

brand names

EPOGEN

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2814
end exclusive: true
exact text: e need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. Epogen is not indicated for patients who are willing to donate autologous blood pre-operatively. 1.5 Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being. Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biolog
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2318

current approval status

not_reconciled

duplicate text group

dup-338899ffaa46215d51d7

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-4ecc2e3fb41c48c96b95

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2614
end exclusive: true
exact text: Epogen is not indicated for patients who are willing to donate autologous blood pre-operatively.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2518

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 15 · limitation of use

application numbers

BLA103234

brand names

EPOGEN

classification reasons

limitation_heading

clinical review status

pending

content role

limitation_of_use

context span

end: 2923
end exclusive: true
exact text: g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. Epogen is not indicated for patients who are willing to donate autologous blood pre-operatively. 1.5 Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being. Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients wi
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2415

current approval status

not_reconciled

duplicate text group

dup-6fa61f7829aba207e0f6

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-d1c0aa9daa537a0c5e89

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2723
end exclusive: true
exact text: 1.5 Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2615

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 16 · limitation of use

application numbers

BLA103234

brand names

EPOGEN

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 3108
end exclusive: true
exact text: is not indicated for patients who are willing to donate autologous blood pre-operatively. 1.5 Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being. Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2524

current approval status

not_reconciled

duplicate text group

dup-70d841767bbcc7c0543e

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-d028683eb9a036f396f4

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2908
end exclusive: true
exact text: Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2724

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 17 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3210
end exclusive: true
exact text: nt well-being. Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In pati
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2709

current approval status

not_reconciled

duplicate text group

dup-ff38cadfb073c97a241b

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-450b8ac5979c5ee3f9f1

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 3010
end exclusive: true
exact text: In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2909

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 18 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3324
end exclusive: true
exact text: logic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediat
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2811

current approval status

not_reconciled

duplicate text group

dup-9b4bf0f04ed1eb3f030f

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-38fd2aa6521cb0a32a3d

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 3124
end exclusive: true
exact text: In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 3011

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 19 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3347
end exclusive: true
exact text: cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediate correction of anemia.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 2925

current approval status

not_reconciled

duplicate text group

dup-d75a9cc94ae4c72e72cb

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-6ef3ace8e421ad31b480

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 3202
end exclusive: true
exact text: In patients scheduled for surgery who are willing to donate autologous blood.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 3125

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 20 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3347
end exclusive: true
exact text: s cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediate correction of anemia.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 3003

current approval status

not_reconciled

duplicate text group

dup-beb5af7d73565ce06779

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-26b867b2dfee229c57e3

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 3254
end exclusive: true
exact text: In patients undergoing cardiac or vascular surgery.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 3203

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 21 · unclassified context

application numbers

BLA103234

brand names

EPOGEN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3347
end exclusive: true
exact text: essive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediate correction of anemia.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 3055

current approval status

not_reconciled

duplicate text group

dup-d10db42eb345e81d2f4f

extraction review status

automated_candidate_pending_source_review

generic names

EPOETIN ALFA

ind-span-f22a9effc025de63a95f

label id

bf994196-5149-4089-b1fc-c4f0cb8744b3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 3347
end exclusive: true
exact text: As a substitute for RBC transfusions in patients who require immediate correction of anemia.
label id: bf994196-5149-4089-b1fc-c4f0cb8744b3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a9a0d4d9b211be6097a8a620c0b0c3f004abc571b1bcfb7cd32464b725f56fca
start: 3255

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf994196-5149-4089-b1fc-c4f0cb8744b3%22

spl effective date

2026-06-23

spl set id

1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5

spl version

137

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice